Health Canada has approved Boehringer Ingelheim‘s oral therapy Jascayd (nerandomilast) as a treatment for adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). “The authorization of JASCAYD marks an important milestone for patients, caregivers and healthcare professionals,” Rasha Eldesouky Abouelabbas, vice president of medical and…
News
Admilparant, an experimental oral therapy being developed by Bristol Myers Squibb, slowed lung function declines among people with idiopathic pulmonary fibrosis (IPF) in a Phase 3 clinical trial. The study, ALOFT-IPF (NCT06003426), enrolled approximately 1,255 adults with IPF ages 40 and older. The trial was open to…
Computer-based analyses of CT scans can help to predict future disease progression and track response to treatment among people with progressive pulmonary fibrosis (PPF), according to a new analysis of clinical trial data. These findings “suggest that quantitative CT methods can facilitate the prediction of clinically relevant outcomes and…
Lower activity of a gene called ZNF331 may help identify obstructive sleep apnea (OSA), marked by repeated stops and starts in breathing during sleep, in people with idiopathic pulmonary fibrosis (IPF), according to a new study by researchers in China. The team found that ZNF331 activity was lowest among people…
AP02, an inhaled form of nintedanib being developed by Avalyn Pharma for idiopathic pulmonary fibrosis (IPF), was generally well tolerated and resulted in higher lung levels of the drug than oral nintedanib, according to findings from two Phase 1 trials. An oral formulation of nintedanib, sold as Ofev,…
An experimental oral treatment called taladegib helped expand lung volume and reduce scarring in people with idiopathic pulmonary fibrosis (IPF), according to a new imaging analysis from a clinical trial. Data from the Phase 2a trial (NCT04968574), generated using artificial intelligence (AI) to evaluate high-resolution chest scans, were…
The U.S. Food and Drug Administration (FDA) will decide by early next year whether or not to expand its approval of nebulized Tyvaso (treprostinil) — an inhaled treatment for people with certain lung diseases — to allow its use in idiopathic pulmonary fibrosis (IPF), a respiratory condition marked…
September is Pulmonary Fibrosis Awareness Month, and advocates around the globe are joining together to shine a light on what it means to live with pulmonary fibrosis (PF), a condition characterized by lung scarring and marked by breathing problems. “It is a lonely feeling to have a chronic disease…
The U.S. Food and Drug Administration (FDA) has given fast track designation to LTI-03, an inhaled therapy candidate that Rein Therapeutics is developing for idiopathic pulmonary fibrosis (IPF). Fast track status is intended to facilitate the development and review of drugs that treat serious conditions and address unmet…
A new type of pericyte called Peri2 is linked to scar tissue formation in the lungs of people with pulmonary fibrosis (PF), according to a study. Pericytes are cells that surround blood vessels. A gene called FOXF1 was also shown to help control whether these cells stay healthy or…
